Navigation Links
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
Date:12/14/2008

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL(R) (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.

Results from this randomized, parallel-group, open-label, multi-center study were presented today at the 31st Annual San Antonio Breast Cancer Symposium (SABCS). The study included only patients previously treated with anthracyclines who had a disease-free interval of at least one year.

The study found that patients treated with the DOXIL and docetaxel combination had a 35% risk reduction for developing disease progression compared with docetaxel alone (hazard ratio = 0.65; 95% confidence interval [0.55, 0.77]; p=0.000001). There is an almost three-month improvement in median TTP for patients treated with the combination compared with docetaxel monotherapy (9.8 versus 7.0 months, respectively).

The safety profile was consistent with known toxicities of the two agents. Additionally, the incidence of symptomatic cardiac events was 5% in the combination group versus 4% in the monotherapy group (>/= Grade 2 cardiac adverse events). Symptomatic congestive heart failure was reported in 1% of subjects in both groups. Arrhythmia was reported in 4% of the combination group and 3% of the monotherapy group. Protocol-defined LVEF decreases occurred in 5% of subjects in both groups.

"Anthracyclines are active drugs for metastatic breast cancer, but concerns about cardiac toxicity have prevented oncologists from using them in those who received anthracyclines as part of their adjuvant therapy," said Dr. Joseph Sparano, Director of the Breast Evaluation Center at the Montefiore-Einstei
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Major deCODE-led Study Underscores Role of the Brain in Obesity
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
4. Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
5. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
6. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
7. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
8. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
9. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
10. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 23 SurgiCount Medical, the wholly-owned operating subsidiary ... PSTX ), announced that results of ... Clinic on their multi-year effort to reduce retained ... two upcoming conferences.  The research and related discussion ...
... Agreement to Develop and... -- ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Mayo Clinic Research on SurgiCount To Be Presented at Conferences 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 3Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 4Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 5Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 6Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 7Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 8Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9
(Date:8/29/2014)... August 29, 2014 As reported by WKMS.com ... Recovery , an Ohio municipal court drug has come up ... Fred Moses, who serves as the presiding judge in a ... makers to offer addicts a medicated treatment option that can ... the drug known as Vivitrol, which blocks receptors in the ...
(Date:8/29/2014)... 29, 2014 According to new research presented ... Peer Pressure, Key to Prescription Drug Misuse Among Young Adults ... for 18-29 year olds when it comes to prescription drug ... this age group the real problem which influences misuse of ... and recreational use of them to have fun with other ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... 2014 Healthpointe has unveiled its new ... the convenience of visiting with physicians online. Anyone can ... , Healthpointe doctors are always available and happy to ... the doctor can even see the patient’s entire family. ... or she can prescribe medications that are available for ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is ... University Physical Therapy students via Clinical Rotations. ... will be shadowing Healthpointe providers and specialists throughout ... to develop clinical experience and learn professional preparation. ... will gain insight into several patient care techniques ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
... , BOYNTON BEACH, Fla. , Feb. ... of this year,s US Open Men,s and Women,s tennis tournament ... http://www.newscom.com/cgi-bin/prnh/20100209/DC52484 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20100120/DC41252LOGO-b ) , Would you ... Golf tournament, complete with airfare and accommodations? , Would you ...
... INDIANAPOLIS -- In the first large-scale epidemiological study of ... researchers from the Indiana University School of Medicine and ... 2010 issue of The Journal of Trauma Injury, ... and opportunities for prevention of these injuries. Nearly ...
... Medical Center are offering pediatric patients diagnosed with chronic ... negative side effects like nausea, fatigue, and vomiting caused ... confluence of Chinese and Western medicine at Rush Children,s ... document how acupuncture might help in reducing pain in ...
... ... Collection Manager™ increases patient safety through accuracy and timeliness , ... (PRWEB) February 9, 2010 ... outreach solutions, announced today that the University of Virginia Health System Medical Laboratories, ...
... D begins in the womb, expert says, , TUESDAY, Feb. ... lots of milk and have a high dietary intake of ... developing multiple sclerosis later in life, researchers say. , The ... about their experiences and diet during pregnancy. The nurses were ...
... , Consumer Watchdog Also Warns Against Insurer-favored ,Cost Solution,: ... Apartment" , WASHINGTON , Feb. 9 ... its premium hikes of up to 39% in California , ... House and an investigation by California ,s insurance commissioner, federal ...
Cached Medicine News:Health News:Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself? 2Health News:Watch your step: Elevator-related injuries and older adults 2Health News:Watch your step: Elevator-related injuries and older adults 3Health News:Young patients with chronic illnesses find relief in acupuncture 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 3Health News:Drinking Milk While Pregnant May Lower Kids' MS Risk 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3
One channel transcranial Doppler...
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
... fine tips and are intended for the most ... The curved ones are ideal for tweezing out ... student versions are for beginners. These Dumont/Swiss watchmaker ... The Swiss forceps are made from the highest ...
Medicine Products: